AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib (palbo) in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER-2) metastatic breast cancer (mBC) Meeting Abstract
| Authors: | Chandarlapaty, S.; Linden, H. M.; Neven, P.; Petrakova, K.; Bardia, A.; Kabos, P.; Braga, S. A. D. S.; Boni, V.; Gosselin, A.; Cartot-Cotton, S.; Doroumian, S.; Celanovic, M.; Cohen, P.; Paux, G.; Campone, M. |
| Abstract Title: | AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib (palbo) in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER-2) metastatic breast cancer (mBC) |
| Meeting Title: | 2021 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2021 Jun 4-8 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-05-20 |
| Language: | English |
| ACCESSION: | WOS:000708120600163 |
| DOI: | 10.1200/JCO.2021.39.15_suppl.1058 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1058 -- Source: Wos |
